首页> 外文期刊>Clinica chimica acta: International journal of clinical chemistry and applied molecular biology >Pretreatment neutrophil-lymphocyte and platelet-lymphocyte ratio predict clinical outcome and prognosis for cervical Cancer
【24h】

Pretreatment neutrophil-lymphocyte and platelet-lymphocyte ratio predict clinical outcome and prognosis for cervical Cancer

机译:预处理中性粒细胞淋巴细胞和血小板淋巴细胞比率预测宫颈癌的临床结果和预后

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Variations in systemic inflammatory response biomarker levels have been associated with adverse clinical outcome in various malignancies. In this study, we aimed to evaluate the predictive and prognostic role of the pretreatment neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) in cervical cancer. We retrospectively investigated 616 patients who underwent initial radical hysterectomy with pelvic lymphadenectomy for cervical cancer between July 2012 and December 2014 in China. Their clinical and histopathological markers and complete blood counts were obtained and analyzed. Then we chose the group of 339 of the total 616 patients who were not combined preoperative radiotherapy or chemotherapy for the survival analysis. Prognostic factors were assessed by univariate and multivariate analyses. The ROC curve revealed NLR and PLR had significant ability to predict parametrial involvement, and the cutoff values for NLR and PLR were 2.5 and 138.8 respectively. Clinicopathologic analysis showed that NLR was linked to age, parametrial involvement, tumor-invasion depth and histologic grade, and PLR was related to age, parametrial involvement, tumor-invasion depth and FIGO stage. Univariate analysis identified high PLR as a significant poor predictor for progression-free survival (PFS) and overall survival (OS), and NLR exhibited no predict power on OS or PFS. Multivariable analysis showed that PLR was an independent predictor of PFS, but not OS. NLR and PLR were associated with the clinical characteristics of cervical cancer. Additionally, PLR had independence prognostic value for PFS in patients with cervical cancer receiving radical hysterectomy with pelvic lymphadenectomy.
机译:全身炎症反应生物标志物水平的变化与各种恶性肿瘤的不良临床结果有关。在这项研究中,我们旨在评估预处理中性粒细胞对淋巴细胞比(NLR)和血小板到淋巴细胞比(PLR)在宫颈癌中的预测和预后作用。我们回顾性地调查了616例患有初始自由基子宫切除术的616名患有骨盆淋巴结切除术2012年7月至2014年12月的宫颈癌。获得并分析了它们的临床和组织病理学标志物和完整的血统计数。然后,我们选择了316例616例患者的339名,该患者未结合术前放疗或化疗进行生存分析。通过单变量和多变量分析评估预后因素。 ROC曲线揭示了NLR和PLR具有显着的能力来预测参数累及,并且NLR和PLR的截止值分别为2.5和138.8。临床病理分析表明,NLR与年龄,参数受累,肿瘤侵袭深度和组织学等学程度相关联,PLR与年龄,参数受累,肿瘤侵入深度和FIGO阶段有关。单变量分析将高PLR鉴定为无进展生存期(PFS)的显着差的预测因子和总存活(OS),NLR在OS或PFS上表现出预测电源。多变量分析表明,PLR是PFS的独立预测因子,但不是OS。 NLR和PLR与宫颈癌的临床特征有关。此外,PLR对宫颈癌接受骨盆淋巴结切除术治疗宫颈癌患者的PFS独立预后价值。

著录项

  • 来源
  • 作者单位

    Chengdu Med Coll Dept Med Imaging Chengdu 610500 Sichuan Peoples R China;

    Sichuan Univ West China Univ Hosp 2 Dept Pathol Chengdu 610041 Sichuan Peoples R China;

    Chengdu Med Coll Dept Med Imaging Chengdu 610500 Sichuan Peoples R China;

    Chengdu Med Coll Dept Med Imaging Chengdu 610500 Sichuan Peoples R China;

    Chengdu Med Coll Dept Med Imaging Chengdu 610500 Sichuan Peoples R China;

    Chengdu Med Coll Dept Med Imaging Chengdu 610500 Sichuan Peoples R China;

    Second Peoples Hosp Chengdu Dept Gen Surg Dept Breast &

    Vasc Surg Chengdu 610017 Sichuan;

    Chengdu Med Coll Dept Pathol &

    Pathophysiol Chengdu 610500 Sichuan Peoples R China;

    Chengdu Med Coll Dept Pathol &

    Pathophysiol Chengdu 610500 Sichuan Peoples R China;

    Chengdu Med Coll Dept Pathol &

    Pathophysiol Chengdu 610500 Sichuan Peoples R China;

    Chengdu Med Coll Dept Pathol &

    Pathophysiol Chengdu 610500 Sichuan Peoples R China;

    Chengdu Med Coll Dept Pathol &

    Pathophysiol Chengdu 610500 Sichuan Peoples R China;

    Chengdu Med Coll Dept Pathol &

    Pathophysiol Chengdu 610500 Sichuan Peoples R China;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 诊断学;
  • 关键词

    Cervical cancer; NLR; PLR; Predict markers; Parametrial involvement; Prognosis;

    机译:宫颈癌;NLR;PLR;预测标志;参数参与;预后;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号